CLX
The Clorox CompanyEvidence as of 2026-09-02Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
+0.8 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
The evidence balance is Constructive (+0.8 of a possible +2; confidence high). Revenue from contracts rose from $ 1,429,000,000 in fiscal Q1 2026 (fiscal quarter ended 2025-10-20) to $ 1,673,000,000 in fiscal Q2 2026 (fiscal quarter ended 2026-01-20) and held essentially flat at $ 1,670,000,000 in fiscal Q3 2026 (fiscal quarter ended 2026-04-16). Gross profit increased from $ 596,000,000 in fiscal Q1 2026 to $ 722,000,000 in fiscal Q2 2026 and remained at $ 722,000,000 in fiscal Q3 2026, while single-quarter net income rose from $ 80,000,000 to $ 157,000,000 and then to $ 187,000,000 across those same quarters.
Diluted EPS moved from $ 0.65 in fiscal Q1 2026 to $ 1.29 in fiscal Q2 2026 and $ 1.54 in fiscal Q3 2026 alongside a decline in weighted‑average diluted shares outstanding from 123,018,000 to 121,787,000. Cash and cash equivalents expanded from $ 166,000,000 as of 2025-09-30 to $ 227,000,000 as of 2025-12-31 and to $ 1,187,000,000 as of 2026-03-31, even as long‑term debt remained roughly stable near $ 2,487,000,000 and stockholders’ equity stayed negative (improving from -$ 125,000,000 as of 2025-12-31 to -$ 67,000,000 as of 2026-03-31).
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Revenue from contracts (single-quarter) rose from $1,429,000,000 in fiscal Q1 2026 (2025-07-01 to 2025-09-30) to $1,673,000,000 in fiscal Q2 2026 (2025-10-01 to 2025-12-31), then was essentially flat at $1,670,000,000 in fiscal Q3 2026 (2026-01-01 to 2026-03-31).
XBRL companyfacts · 0000021076-25-000053Gross profit (single-quarter) increased from $596,000,000 in fiscal Q1 2026 (2025-07-01 to 2025-09-30) to $722,000,000 in fiscal Q2 2026 (2025-10-01 to 2025-12-31) and remained at $722,000,000 in fiscal Q3 2026 (2026-01-01 to 2026-03-31).
XBRL companyfacts · 0000021076-26-000010Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Nothing in this slice of the evidence rose to a claim — a quiet read, which itself is information.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
No computed signal history for this symbol yet — signals need roughly 70 trading days of price history.
Reads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
As of 2026-09-02T13:45:47.228469+00:00, the company is a constituent of the ETF with symbol IVV.
ETF constituents · market dataThe company's weight in that ETF was 0.02% of the fund as of 2026-09-02T13:45:47.228469+00:00, indicating a very small position within IVV.
ETF constituents · market dataReads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Multiple outlets ran the same headline noting Clorox was down ~9.3% since its last earnings report, framing coverage around the stock’s post-earnings decline.
News · finance.yahoo.com · 2026-09-02At least two value-focused pieces compare Clorox to peers and ask whether it is a better value stock, indicating the coverage emphasizes valuation comparisons.
News · finance.yahoo.com · 2026-09-01Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
No insider transactions on file in the trailing 180 days.
Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
Free cash flow (TTM) is $367,000,000 and free cash flow per share (TTM) is $3.0135.
Valuation inputs · SEC XBRL + stored EOD closeEarnings per share (TTM) is $4.98.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
The evidence shows sequential improvement in core operating results across three quarters: revenue rose and then held steady, gross profit increased and remained elevated, and net income and diluted EPS more than doubled from Q1 to Q3 2026 while weighted-average diluted shares declined. Cash and cash equivalents expanded materially by Q3 2026, supported by reported share repurchases in Q1, and operating cash flow and trailing free cash flow are positive on a TTM basis. These company-specific financial improvements and buyback activity together support a favorable fundamental read versus framing the story solely around post-earnings price moves or valuation headlines.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.37
22 surviving claims rest on 11 distinct sources; the heaviest analyst carries 41% of them, and 100% of what the desk raised survived the debate.
The surviving read relies on a moderate number of distinct sources but a notable share of claims trace back to a single analyst voice, and every point the desk raised survived internal challenge — together this raises the risk that the set is coherent but somewhat brittle to a few key inputs. Source concentration and analyst dependence mean the read should be treated as informative but weight-limited: additional independent filings or third‑party data would materially strengthen confidence.
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
12 filings· 2 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer+0.7 to the score
1 holdings record
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+1.0 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only — it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on CLX Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.